U.S. Healthcare Contract Research Organization Market

IQVIA removed about USD 2.1 billion of inactive trials from its research and development backlog after “a detailed review”, yet still booked USD 3.2 billion of new work, up 15%, for a book-to-bill ratio of 1.2x in the quarter to 30 September 2026, its results of 27 October 2026 show; two days later Fortrea cut USD 558 million from its own backlog in a similar contract review, its release of 29 October 2026 states. The U.S. healthcare contract research organization (CRO) market covers outsourced research services bought by drug, biologic and medical device sponsors in the United States: preclinical discovery and safety work, Phase I to Phase III clinical trial management, central laboratory and bioanalytical testing, late-phase and real-world evidence studies, and regulatory and medical writing support. Douglas Insights sizes it at USD 25.4 billion in 2025, about 130,000 billable full-time-equivalent (FTE) staff years multiplied by an average USD 195,000 per FTE-year, and at USD 44.0 billion in 2035, a 5.68% compound annual growth rate (CAGR). The study is the United States row of our worldwide Healthcare Contract Research Organization Market model and sits in our pharmaceuticals coverage, beside the U.S. Pharmaceutical Drug Market, U.S. Upstream Bioprocessing Market and Computational Biology Market reports; every figure follows the Douglas Insights research methodology.

Which U.S. healthcare contract research organization service earns the most: Phase II-III trials, preclinical safety or central labs?

Phase II-III clinical trial services earn the most, 51.5% of 2025 U.S. CRO value or about USD 13.1 billion, Douglas Insights estimates. Late-phase and real-world evidence studies grow fastest, at 7.10% a year to 2035.

Phase II-III work dominates because a pivotal trial runs for three to five years across 100 or more sites, and sponsors pay a CRO for site selection, monitoring, data management, biostatistics and pharmacovigilance throughout. At 5.85% a year the segment grows to USD 23.1 billion by 2035, a Douglas Insights estimate. Preclinical discovery and safety assessment, USD 4.31 billion, grows slowest at 4.20%: Charles River Laboratories said organic revenue in its Discovery and Safety Assessment (DSA) segment rose 5.9% to USD 596.3 million in the quarter to 26 September 2026, while reported DSA revenue fell 0.7%, its results of 4 November 2026 show, and the Food and Drug Administration (FDA) is steering sponsors toward non-animal methods.

Central laboratory and bioanalytical testing, USD 2.66 billion, follows trial volume at 5.65%. Phase I early clinical services, USD 2.03 billion, grow 6.40% as more first-in-human studies return to American clinics. Late-phase and real-world evidence studies, USD 1.90 billion, grow fastest at 7.10% because payers and the FDA ask for post-approval safety and outcomes data. Regulatory, medical writing and consulting work, USD 1.39 billion, grows 5.40%. Service values for 2035 sum to USD 44.1 billion, 0.08% above the headline.

Who buys U.S. healthcare CRO services: emerging biotechs, large pharma or device makers?

Small and mid-sized biotechnology companies buy about 46.0% of U.S. healthcare CRO value, roughly USD 11.7 billion in 2025, Douglas Insights estimates. Large pharmaceutical companies take 41.0%, device and diagnostics makers 8.0% and academic and government sponsors 5.0%.

Emerging biotechs are the core buyer because most of them have no clinical operations staff and outsource the whole trial. Medpace, the CRO most exposed to this group, drew 82% of its 2025 net revenue from small biopharmaceutical companies, those with less than USD 250 million of sales, and 13% from mid-sized companies, its annual report for 2025 states. The same filing says Medpace drew 35.1% of revenue from its top ten customers. Douglas Insights models the biotech share rising to about 51% by 2035, growing 6.70% a year to USD 22.3 billion.

Large pharmaceutical companies, USD 10.4 billion, grow 4.70% a year. They buy through preferred-provider deals with two or three full-service CROs and keep more design and data work in-house, so price pressure is sharper. Device and diagnostics makers, USD 2.03 billion, grow 5.40% as the FDA asks for more clinical evidence for higher-risk devices. Academic and government sponsors, USD 1.27 billion, grow 3.20%, the slowest, because federal research grants are tight. Buyer values for 2035 sum to USD 43.9 billion, 0.26% below the headline.

What drives U.S. healthcare contract research organization demand: biotech outsourcing, a bookings rebound or new trial rules?

U.S. healthcare CRO volume rises 3.00% a year in our base case, from about 130,000 billable FTE-years in 2025 to 175,000 in 2035. Four drivers add 3.90 points of gross volume growth before restraints remove 0.90 points.

Biotech outsourcing depth: 1.30 points

Biotech outsourcing is the largest driver, worth 1.30 points. Medpace, which serves mostly small biotechs, won USD 873.4 million of net new business awards in the quarter to 30 September 2026, up 10.6%, and raised its 2026 revenue guidance to USD 2.835 billion to USD 2.855 billion, growth of 12.0% to 12.8% over the USD 2.530 billion of 2025, its results of 21 October 2026 show. A biotech with one Phase II asset and 40 staff buys roughly 60 to 90 CRO FTE-years a year to run that trial, a Douglas Insights estimate, so every newly funded company adds directly to outsourced volume.

Bookings rebound at full-service CROs: 1.10 points

The bookings rebound adds 1.10 points. ICON’s gross business wins rose 26.9% to USD 3.79 billion in the quarter to 30 September 2026, and after USD 639 million of cancellations its net wins of USD 3.15 billion gave a book-to-bill of 1.56x and a backlog of USD 24.5 billion, its results of 27 October 2026 show. IQVIA’s trailing twelve-month net new bookings reached USD 11.7 billion, up 14%, and it expects about USD 9.4 billion of backlog to turn into revenue in the next twelve months, 10% more than a year earlier, its 27 October 2026 release states.

Risk-based trial rules under ICH E6(R3): 0.80 points

New good clinical practice rules add 0.80 points. The FDA announced final guidance E6(R3) Good Clinical Practice, written under the International Council for Harmonisation (ICH), in the Federal Register on 9 September 2025, stressing quality by design, proportionality and risk-based approaches, clarifying remote and electronic consent and the duties sponsors delegate to service providers. Sponsors that must now document risk plans, data governance and vendor oversight lean on CROs that already run central monitoring, adding about 1,400 FTE-years a year by 2030, a Douglas Insights estimate.

BIOSECURE reshoring of laboratory work: 0.70 points

Reshoring adds the last 0.70 points. The BIOSECURE Act, section 851 of the National Defense Authorization Act for fiscal 2026, became law on 18 December 2025 and bars federal contracts and grants from paying for biotechnology services of designated companies of concern, with the Office of Management and Budget (OMB) due to publish its list by 18 December 2026, a Latham & Watkins analysis of 31 December 2025 explains. Summed, 1.30 + 1.10 + 0.80 + 0.70 = 3.90 points, a Douglas Insights estimate; after restraints, the 3.00% volume leg multiplied by the 2.60% price leg gives the 5.68% revenue rate.

What holds back the U.S. healthcare CRO market: cancelled trials, fewer animal studies or pricing pressure?

Three restraints remove 0.90 points a year from U.S. healthcare CRO volume growth: inactive and cancelled trials take 0.40 points, the FDA shift away from animal testing 0.25 points, and sponsor price pressure and automation 0.25 points.

Dead trials are the heaviest drag. IQVIA’s USD 2.1 billion adjustment and Fortrea’s USD 558 million cut together removed about USD 2.66 billion of work, roughly 6.2% of the two companies’ combined pre-adjustment backlog, a Douglas Insights calculation from their October 2026 releases. Fortrea said its adjustment reflected “the cumulative impact of estimated scope and study delivery requirements across customer contracts, including inactive trials”, its 29 October 2026 release states. ICON’s cancellations of USD 639 million equalled 16.9% of its gross wins in the same quarter.

Animal studies are the second drag. The FDA said on 10 April 2025 that it would phase out the animal testing requirement for monoclonal antibodies and other drugs, using AI-based toxicity models, cell lines and organoids, with immediate effect for investigational new drug applications. Fewer non-human primate studies mean fewer billable safety assessment hours, worth 0.25 points. Large sponsors pushing unit prices down, and AI tools that cut monitoring and medical writing hours by 10% to 20% per study, a Douglas Insights estimate, take the final 0.25 points.

Which U.S. region buys the most healthcare CRO services, and where does value grow fastest?

The Northeast buys the most U.S. healthcare CRO value, USD 8.62 billion or 34.0% of 2025 sales by sponsor location. The West grows fastest, at 6.15% a year to USD 12.2 billion by 2035, on California biotech pipelines.

The Northeast leads because Massachusetts, New Jersey, New York and Pennsylvania hold the densest cluster of biotech headquarters and large-pharma research centres in the country, from Cambridge to the Route 1 corridor. It grows 5.35%, below the national rate, because its large-pharma share is highest. The West, USD 6.72 billion, grows fastest at 6.15% on the San Francisco Bay Area and San Diego biotech clusters, which rely almost entirely on outsourced trials.

The South, USD 6.34 billion, grows 5.95%. North Carolina’s Research Triangle hosts the U.S. operations of several large CROs, Texas has fast-growing oncology trial networks in Houston and Dallas, and Florida runs many Phase I units. The Midwest, USD 3.68 billion, grows 4.90%; Medpace is based in Cincinnati and Charles River runs safety sites in Ohio, but sponsor spending there is smaller. Regional values sum to USD 26.8 billion in 2026 and USD 43.9 billion in 2035, 0.21% below the headline.

Which companies lead the U.S. healthcare contract research organization market, and how concentrated is it?

IQVIA leads the U.S. healthcare CRO market with about 16.5% of 2025 value, a Douglas Insights estimate, ahead of ICON at 13.5% and Thermo Fisher Scientific’s PPD clinical research business at 11.0%. The top three hold about 41.0%.

IQVIA grew R&D Solutions revenue 8.7% to USD 2.64 billion in the quarter, held USD 32.6 billion of contracted backlog and raised its 2026 company revenue guidance to USD 17.35 billion to USD 17.50 billion, its 27 October 2026 release shows; chairman and chief executive Ari Bousbib said “IQVIA delivered another record quarter”. ICON’s revenue fell 2.9% to USD 2.02 billion, but its 1.56x book-to-bill points to growth in 2027, and it guides 2026 revenue at USD 8.10 billion to USD 8.20 billion.

Fortrea’s revenue slipped to USD 691.5 million from USD 701.3 million, with a 1.12x book-to-bill and guidance of USD 2.665 billion to USD 2.690 billion; chief executive Anshul Thakral said “our sustained bookings momentum is building a foundation for growth”. Charles River’s chief executive Birgit Girshick said the company was “encouraged by the continued strength of the biopharmaceutical demand environment”. Thermo Fisher, Syneos Health and Parexel do not publish U.S. CRO revenue, so their shares, and every share in the table, are Douglas Insights estimates.

How much do U.S. healthcare CRO services cost per FTE-year, and how fast do rates rise?

U.S. healthcare CRO services cost an average USD 195,000 per billable FTE-year in 2025, Douglas Insights estimates, from about USD 150,000 for laboratory staff to USD 255,000 for medical and biostatistics roles. The blended price leg rises 2.60% a year.

The FTE-year is how sponsors and CROs price most trial work: a budget lists clinical research associates, project managers, data managers, statisticians and medical monitors by hours, then adds fixed fees for set-up and close-out. Douglas Insights puts a clinical research associate at about USD 180,000 a year, a project manager at about USD 225,000 and a medical monitor or biostatistician at about USD 255,000, all fully loaded with overhead and margin.

The price leg reaches about USD 200,100 per FTE-year in 2026 and USD 252,100 in 2035. Two forces hold it near 2.60%: wage inflation for experienced research associates, which pushes rates up 3% to 4% a year, and large-sponsor procurement plus AI-assisted monitoring, which pull about 1 point back. Medpace converted 23.8% of its opening backlog into revenue in the September 2026 quarter, its October release shows.

Preclinical prices behave differently. A regulated toxicology study is quoted per study, not per FTE-year, and its price depends heavily on animal model costs; Douglas Insights converts DSA revenue to FTE-years at about USD 150,000 each, the lowest rate in the model, and expects that rate to rise faster, about 3.4% a year, as studies shift to in vitro and computational methods that need more scientists per study.

Will the BIOSECURE Act shift preclinical and lab work from China to U.S. healthcare CROs?

Partly. Douglas Insights estimates the BIOSECURE Act moves about USD 900 million of yearly preclinical and laboratory spending to U.S. providers by 2032, roughly 4,600 FTE-years, once OMB names companies of concern and the five-year safe harbor runs out.

The law, enacted on 18 December 2025, reaches companies already on the Department of Defense 1260H list 60 days after federal acquisition rules are updated and companies added later 90 days after that update, with a five-year safe harbor for existing contracts, the Latham & Watkins analysis notes. The direct effect falls on federal contracts and grants, but American biotechs that hope to sell to federal buyers, or be acquired by those who do, are already asking CROs for supply chains with no designated provider.

Beneficiaries are U.S. safety assessment and bioanalytical laboratories, led by Charles River, Labcorp and Inotiv, and the central laboratory arms of IQVIA and Thermo Fisher. The shift is slow because the safe harbor runs for five years from the acquisition rule update, so Douglas Insights spreads the 0.70-point driver evenly across 2026 to 2032 rather than front-loading it.

Which rules govern U.S. healthcare CROs, from ICH E6(R3) to BIOSECURE and the FDA animal testing roadmap?

Three federal layers govern U.S. healthcare CROs: ICH E6(R3) good clinical practice guidance of 9 September 2025, the FDA animal testing roadmap of 10 April 2025 and the BIOSECURE Act of 18 December 2025.

The trial layer is the oldest. FDA regulations at 21 CFR Part 312 let a sponsor transfer trial obligations to a contract research organization in writing, and any obligation not transferred stays with the sponsor. E6(R3), which finalised a June 2023 draft, keeps that structure but rewrites the guidance around risk proportionality, data governance and oversight of service providers, so CRO contracts now carry detailed quality-management and data-handling terms.

The preclinical layer is changing fastest. The FDA roadmap lets sponsors submit new approach methodologies (NAMs) data, such as computational toxicity models and organoid tests, in investigational new drug applications at once, which favours CROs with in vitro and modelling capacity over those built only around animal studies. The security layer, BIOSECURE, applies through federal procurement and grants, with the OMB list due by 18 December 2026, and the Latham & Watkins analysis notes it allows agency waivers of up to 365 days.

What if biotech funding stalls or bookings keep surging: how large is the U.S. healthcare contract research organization market in 2035?

The U.S. healthcare CRO market ends 2035 between USD 36.2 billion and USD 52.9 billion across our three cases, around a base of USD 44.0 billion. Biotech funding and cancellation rates set most of the spread.

In the slower case venture funding for biotechs dries up again, cancellations stay near the 16.9% of gross wins ICON saw in the September 2026 quarter, and AI tools cut billable hours faster, taking 1.40 points off the volume leg. In the faster case bookings like ICON’s 1.56x and IQVIA’s 1.2x persist through 2028, and BIOSECURE reshoring arrives early. One extra point of yearly revenue growth adds about USD 4.35 billion to 2035 value.

Company signals bracket the base case. IQVIA’s R&D Solutions revenue grew 8.7% and Medpace’s revenue 8.5% in the September 2026 quarter, while ICON’s fell 2.9% and Fortrea’s about 1.4%, the four companies’ filings show; our 5.68% revenue rate sits inside that range, weighted toward the full-service leaders that dominate U.S. work. It is below the 8.5% to 8.7% quarterly growth IQVIA and Medpace reported because their figures include reimbursed pass-through costs, acquisitions and work outside the United States, which this study excludes, and because one strong quarter does not set a ten-year rate.

Douglas Exclusive: the American CRO Backlog Burn Ledger

The Backlog Burn Ledger is a Douglas Insights model built from 12 inputs, 9 company filings and 3 federal rules, listed below. It measures how many quarters of revenue American CRO backlogs really cover once dead trials are removed.

The finding, a Douglas Insights estimate: about one dollar in every 16 of reported large-CRO backlog was tied to trials that were no longer running. IQVIA’s USD 2.1 billion and Fortrea’s USD 558 million reviews removed 6.2% of their combined pre-review backlog of USD 42.6 billion. After the cleanup, IQVIA’s backlog covers 12.4 quarters of R&D Solutions revenue, ICON’s 12.1 and Fortrea’s 10.6, while Medpace’s covers only 4.4 quarters on its reported figures, because biotech trials are booked later and burn faster.

The ledger changes how to read bookings. A 1.2x or 1.56x book-to-bill now rests on cleaner backlogs, so Douglas Insights treats the 2026 bookings rebound as real volume rather than paper, which supports the 1.10-point driver.

How does the methodology turn 130,000 FTE-years into USD 25.4 billion?

Our methodology multiplies about 130,000 billable U.S. healthcare CRO FTE-years by an average USD 195,000 per FTE-year to reach USD 25.4 billion in 2025, then grows volume 3.00% and price 2.60% a year.

The model covers 6 services, 4 buyer groups and 4 Census regions, using 64 data points, 21 sourced and 43 modelled. FTE-years come from the U.S. share of revenue at the six named companies, converted at role-weighted rates, plus private CROs such as Syneos Health, Parexel and hundreds of specialist firms, all Douglas Insights estimates. Arithmetic: 130,000 x USD 195,000 = USD 25.35 billion; USD 25.35 billion x (1.030 x 1.026)^10 = USD 44.0 billion. Volume reaches about 133,900 FTE-years in 2026 and 174,700 in 2035.

Two cross-checks agree. First, USD 25.35 billion is 91.0% of the USD 27.85 billion North America row in our worldwide model; with Canada at USD 2.50 billion the two make that row, and Canada’s implied 4.78% rate keeps North America at 5.60% a year to USD 48.0 billion in 2035. Second, our base revenue rate of 5.68% sits inside the band of reported third-quarter 2026 growth rates, from minus 2.9% at ICON to 8.7% at IQVIA R&D Solutions, with forward signals such as IQVIA’s 10% next-twelve-month conversion growth near the top. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. IQVIA via SEC EDGAR IQVIA reports third-quarter 2026 results (2026)
2. Medpace via SEC EDGAR Medpace Holdings reports third quarter 2026 results (2026)
3. SEC EDGAR Medpace Holdings Form 10-K for 2025 (2026)
4. Charles River via SEC EDGAR Charles River Laboratories third-quarter 2026 results (2026)
5. ICON plc (Business Wire release) ICON reports third quarter 2026 results (2026)
6. Fortrea (GlobeNewswire release) Fortrea reports third quarter 2026 results (2026)
7. Federal Register, US Food and Drug Administration E6(R3) Good Clinical Practice; guidance for industry; availability (2025)
8. US Food and Drug Administration FDA announces plan to phase out animal testing requirement for monoclonal antibodies and other drugs (2025)
9. Latham & Watkins BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (2025)

What counts in the U.S. healthcare CRO study, and what is excluded?

The U.S. healthcare contract research organization study counts outsourced preclinical, clinical, laboratory, late-phase and regulatory research services bought for drugs, biologics and medical devices in the United States, valued at service fees. Contract manufacturing, investigator grants and in-house sponsor research are excluded.

The study splits value by 6 services, 4 buyer groups and the 4 Census regions: Northeast, West, South and Midwest. Contract manufacturing of biologics appears in our U.S. Upstream Bioprocessing Market report, and cell line work in our Cell Line Development Market report.